DGM
JBIO

Darwin Global Management’s Jade Biosciences JBIO Stock Holding History

Darwin Global Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-357
Closed -$262K – 14
2021
Q3 		$262K Buy
+357
New +$200K 0.05% 12

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Darwin Global Management's JBIO Position: Q4 2021 in Review

Darwin Global Management sold out of Jade Biosciences (JBIO) in Q4 2021, closing a stake of 357 shares — an estimated $262K sold.

Darwin Global Management first reported a position in JBIO in Q3 2021 and held it in 1 quarter. The position peaked at $262K in Q3 2021. 47 funds tracked by Wall St. Rank hold JBIO as of Q4 2021.

  • Darwin Global Management reported no remaining Jade Biosciences position as of Q4 2021 after selling out during the quarter.
  • Darwin Global Management sold 357 Jade Biosciences shares in Q4 2021, an estimated $262K.
  • Darwin Global Management first reported a position in Jade Biosciences in Q3 2021 and held it in 1 quarter.
  • Darwin Global Management's Jade Biosciences position peaked at $262K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2021.

Based on Darwin Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.